142 related articles for article (PubMed ID: 2347058)
21. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
22. Activity of ifosfamide in breast cancer.
Hortobagyi GN
Semin Oncol; 1992 Dec; 19(6 Suppl 12):36-41. PubMed ID: 1485173
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.
Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656
[TBL] [Abstract][Full Text] [Related]
24. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin.
Gurney H; Harnett P; Kefford R; Boyages J
Aust N Z J Med; 1998 Jun; 28(3):400-2. PubMed ID: 9673758
[TBL] [Abstract][Full Text] [Related]
26. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Toma S; Palumbo R; Canavese G; Albanese E; Cantoni E; Barisone A; Reggiardo G; Rosso R; Santi L
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S222-7. PubMed ID: 8453703
[TBL] [Abstract][Full Text] [Related]
27. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
[TBL] [Abstract][Full Text] [Related]
28. The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Lind MJ; Gumbrell L; Cantwell BM; Millward MJ; Simmonds D; Proctor M; Chapman F; McCann E; Middleton I; Calvert AH
Br J Cancer; 1995 Mar; 71(3):610-3. PubMed ID: 7533518
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
30. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
31. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
[TBL] [Abstract][Full Text] [Related]
32. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.
Reichardt P; Tilgner J; Hohenberger P; Dörken B
J Clin Oncol; 1998 Apr; 16(4):1438-43. PubMed ID: 9552049
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
Eur J Cancer; 1992; 29A(1):37-43. PubMed ID: 1445744
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek G; Raderer M; Koperna-Mach K; Müller C; Karner J; Kastner J; Tetzner C
J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R7-10. PubMed ID: 8698741
[TBL] [Abstract][Full Text] [Related]
37. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
38. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
39. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
Fountzilas G; Papadimitriou C; Aravantinos G; Nicolaides C; Stathopoulos G; Bafaloukos D; Kalofonos H; Ekonomopoulos T; Skarlos D; Pavlidis N; Dimopoulos AM
Oncology; 2001; 60(3):214-20. PubMed ID: 11340372
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer.
Fountzilas G; Pectasides D; Christodoulou C; Timotheadou E; Economopoulos T; Papakostas P; Papadimitriou C; Gogas H; Efstratiou I; Skarlos D
Med Oncol; 2006; 23(4):479-88. PubMed ID: 17303906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
